Revised Guidance, Development Milestones, Appointment, Program Extension, and Event Schedules - Research Reports on Mylan, Tekmira, GSK, Cigna and WellPoint

NEW YORK, October 8, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Mylan, Inc. (NASDAQ: MYL), Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR), GlaxoSmithKline plc (NYSE: GSK), Cigna Corp. (NYSE: CI) and WellPoint Inc. (NYSE: WLP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7013-100free.

--
Mylan, Inc. Research Reports
On October 3, 2014, Mylan, Inc. (Mylan) announced an upward revision to its Q3 2014 adjusted diluted EPS guidance range, citing stronger than expected operational performance during the quarter on back of multiple product approvals and launches in the U.S. The Company now expects Q3 2014 adjusted diluted EPS to be in the range of $1.12 to $1.16 per share, versus previously forecasted range of $0.90 to $0.95. The increased guidance range for the Q3 2014 also includes c.$0.14 per share as a result of an agreement with Strides Arcolab Limited. In addition, the Company also raised its full-year 2014 adjusted diluted EPS guidance from a range of $3.25 to $3.45 per share to a range of $3.44 to $3.54 per share. Mylan is scheduled to report its Q3 2014 financial results on October 30, 2014, after the market closes. Following the announcement, the Company's stock gained 8.02% to end at $50.23. The full research reports on Mylan are available to download free of charge at:

http://www.analystsreview.com/Oct-08-2014/MYL/report.pdf

--
Tekmira Pharmaceuticals Corp. Research Reports
On October 2, 2014, Tekmira Pharmaceuticals Corp. (Tekmira) announced that it has achieved a development milestone supporting a $1.5 million payment from Monsanto, following completion of specified program objectives. The Company informed that the work is a part of the research program under the Option Agreement signed between Tekmira and Monsanto, relating to Tekmira's proprietary delivery technology and intellectual property for use in agricultural applications. According to the Company, the potential value of the transaction could reach up to $86.2 million, following the successful completion of all program milestones. The full research reports on Tekmira are available to download free of charge at:

http://www.analystsreview.com/Oct-08-2014/TKMR/report.pdf

--
GlaxoSmithKline plc Research Reports
On October 3, 2014, GlaxoSmithKline plc (GSK) announced the appointment of Urs Rohner to its Board as a Non-Executive Director, effective January 1, 2015. On appointment, Rohner will also become a member of GSK's Remuneration Committee. GSK informed that Rohner is currently serving as Chairman of Credit Suisse Group AG. Commenting on the appointment, Sir Christopher Gent, Chairman of GSK, said: "I am delighted to welcome Urs to the Board. His broad business background and extensive senior-level experience at multinational companies makes him a great addition to GSK." The full research reports on GSK are available to download free of charge at:

http://www.analystsreview.com/Oct-08-2014/GSK/report.pdf

--
Cigna Corp. Research Reports
On October 2, 2014, Cigna Corp. (Cigna) informed that its subsidiary Cigna-HealthSpring is expanding its population health program that utilizes interactive tablets - the Intel-GE Care Innovations™ Guide - and virtual connection to Cigna-HealthSpring nurse practitioners to partner and engage with patients diagnosed with congestive heart failure (CHF) to successfully manage their condition at home. The Company informed that the program is now being implemented with 250 patients statewide with potential for further expansion. Under the expanded program, participating Cigna-HealthSpring customers will be given a blood pressure cuff, scale and interactive tablet for a minimum of 90 days which will enable them to interact virtually with their Cigna-HealthSpring nurse practitioner, track their daily biometrics and complete an educational program to help them manage their CHF at home. The full research reports on Cigna are available to download free of charge at:

http://www.analystsreview.com/Oct-08-2014/CI/report.pdf

--
WellPoint Inc. Research Reports
On September 30, 2014, WellPoint Inc. (WellPoint) announced that it will release its Q3 2014 financial results on October 29, 2014 at 6:00 a.m. EDT, which will be followed by a conference call at 8:30 a.m. EDT on the same day to discuss the results and outlook. On average, analysts polled by Bloomberg Businessweek expect WellPoint's Q3 2014 EPS at $2.27. The full research reports on WellPoint are available to download free of charge at:

http://www.analystsreview.com/Oct-08-2014/WLP/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review